Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience.
- DOI
- 10.1016/j.gore.2026.102198
- Published
- 2026-09-11
- Container
- Gynecol Oncol Rep
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.gore.2026.102198,
title = {Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience.},
author = {Amondarain Amenabar N and Mujika Eizmendi K and Gabirondo Amenabar L and Crespo Cruz M and Muñagorri Quiles I and Gutiérrez San José E and García Álvarez M and Arrondo Arizmendi I and Bengoa Fernández N and Martínez Amorena J and Sánchez Urrestarazu M and Egaña Otaño L and Churruca Galaz C.},
year = {2026},
journal = {Gynecol Oncol Rep},
doi = {10.1016/j.gore.2026.102198},
url = {https://doi.org/10.1016/j.gore.2026.102198}
}RIS
TY - JOUR TI - Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience. AU - Amondarain Amenabar N AU - Mujika Eizmendi K AU - Gabirondo Amenabar L AU - Crespo Cruz M AU - Muñagorri Quiles I AU - Gutiérrez San José E AU - García Álvarez M AU - Arrondo Arizmendi I AU - Bengoa Fernández N AU - Martínez Amorena J AU - Sánchez Urrestarazu M AU - Egaña Otaño L AU - Churruca Galaz C. PY - 2026 JO - Gynecol Oncol Rep DO - 10.1016/j.gore.2026.102198 UR - https://doi.org/10.1016/j.gore.2026.102198 ER -
APA
N, A. A., K, M. E., L, G. A., M, C. C., I, M. Q., E, G. S. J., M, G. Á., I, A. A., N, B. F., J, M. A., M, S. U., L, E. O., & C., C. G. (2026). Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience.. Gynecol Oncol Rep. https://doi.org/10.1016/j.gore.2026.102198
Source records
- europe-pmc · retrieved 2026-09-26T10:57:22.651Z